MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- AUROBINDO PHARMA - MYLAN (US)
AUROBINDO PHARMA vs MYLAN (US) - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 AUROBINDO PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-19 |
MYLAN Dec-18 |
AUROBINDO PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 830 | 3,410 | - | |
| Low | Rs | 527 | 1,877 | - | |
| Sales per share (Unadj.) | Rs | 333.9 | 1,568.9 | - | |
| Earnings per share (Unadj.) | Rs | 40.4 | 42.6 | - | |
| Cash flow per share (Unadj.) | Rs | 51.8 | 336.4 | - | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 237.1 | 1,697.3 | - | |
| Shares outstanding (eoy) | m | 585.91 | 514.50 | - | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.0 | 1.7 | 120.6% | |
| Avg P/E ratio | x | 16.8 | 62.0 | 27.1% | |
| P/CF ratio (eoy) | x | 13.1 | 7.9 | 166.8% | |
| Price / Book Value ratio | x | 2.9 | 1.6 | 183.8% | |
| Dividend payout | % | 6.2 | 0 | - | |
| Avg Mkt Cap | Rs m | 397,569 | 1,359,899 | 29.2% | |
| No. of employees | `000 | 17.9 | 35.0 | 51.0% | |
| Total wages/salary | Rs m | 25,849 | 0 | - | |
| Avg. sales/employee | Rs Th | 10,956.9 | 23,062.8 | 47.5% | |
| Avg. wages/employee | Rs Th | 1,447.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,324.3 | 626.3 | 211.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 195,636 | 807,198 | 24.2% | |
| Other income | Rs m | 1,553 | 0 | - | |
| Total revenues | Rs m | 197,189 | 807,198 | 24.4% | |
| Gross profit | Rs m | 39,519 | 208,873 | 18.9% | |
| Depreciation | Rs m | 6,680 | 151,139 | 4.4% | |
| Interest | Rs m | 2,626 | 38,823 | 6.8% | |
| Profit before tax | Rs m | 31,767 | 18,910 | 168.0% | |
| Minority Interest | Rs m | 27 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
| Tax | Rs m | 7,269 | -3,008 | -241.6% | |
| Profit after tax | Rs m | 23,645 | 21,919 | 107.9% | |
| Gross profit margin | % | 20.2 | 25.9 | 78.1% | |
| Effective tax rate | % | 22.9 | -15.9 | -143.8% | |
| Net profit margin | % | 12.1 | 2.7 | 445.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 153,645 | 450,739 | 34.1% | |
| Current liabilities | Rs m | 120,429 | 328,638 | 36.6% | |
| Net working cap to sales | % | 17.0 | 15.1 | 112.2% | |
| Current ratio | x | 1.3 | 1.4 | 93.0% | |
| Inventory Days | Days | 135 | 84 | 161.8% | |
| Debtors Days | Days | 64 | 93 | 68.3% | |
| Net fixed assets | Rs m | 103,909 | 156,583 | 66.4% | |
| Share capital | Rs m | 586 | 430 | 136.3% | |
| Net worth | Rs m | 138,908 | 873,241 | 15.9% | |
| Long term debt | Rs m | 1,800 | 942,508 | 0.2% | |
| Total assets | Rs m | 264,544 | 2,342,373 | 11.3% | |
| Interest coverage | x | 13.1 | 1.5 | 880.7% | |
| Debt to equity ratio | x | 0 | 1.1 | 1.2% | |
| Sales to assets ratio | x | 0.7 | 0.3 | 214.6% | |
| Return on assets | % | 9.9 | 2.6 | 383.0% | |
| Return on equity | % | 17.0 | 2.5 | 678.2% | |
| Return on capital | % | 23.8 | 3.2 | 749.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,220 | 167,736 | 9.7% | |
| From Investments | Rs m | -28,768 | -86,701 | 33.2% | |
| From Financial Activity | Rs m | 19,191 | -78,141 | -24.6% | |
| Net Cashflow | Rs m | 6,656 | 1,390 | 479.0% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.63 Rs / USD
Compare AUROBINDO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: ABBOTT INDIA FDC LTD. CADILA HEALTHCARE IPCA LABS ORCHID PHARMA LTD
Today's Market
Sensex Crashes 807 Points on Coronavirus Fears; Metal and Automobile Stocks Fall(Closing)
Indian share markets fell sharply today, tracking a global selloff as coronavirus cases spiked outside China.
Related Views On News
AUROBINDO PHARMA Plunges by 16%; BSE HEALTHCARE Index Down 1.4% (Market Updates)
Feb 24, 2020 | Updated on Feb 24, 2020AUROBINDO PHARMA share price has plunged by 16% and its current market price is Rs 540. The BSE HEALTHCARE is down by 1.4%. The top gainers in the BSE HEALTHCARE Index are SHILPA MEDICARE (up 5.0%) and SUVEN LIFESCIENCES (up 4.9%). The top losers is AUROBINDO PHARMA (down 15.6%)..
AUROBINDO PHARMA Plunges by 10%; BSE HEALTHCARE Index Down 0.6% (Market Updates)
Feb 24, 2020 | Updated on Feb 24, 2020AUROBINDO PHARMA share price has plunged by 10% and its current market price is Rs 540. The BSE HEALTHCARE is down by 0.6%. The top gainers in the BSE HEALTHCARE Index are SUVEN LIFESCIENCES (up 4.9%) and FDC LTD. (up 4.6%). The top losers is AUROBINDO PHARMA (down 10.0%)..
AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)
Feb 7, 2020 | Updated on Feb 7, 2020For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsMost Popular
The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks (Profit Hunter)
Feb 19, 2020While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.
This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years) (Profit Hunter)
Feb 11, 2020A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.
Here's Why I Recommended 15 Stocks in One Day Flat 
(Views On News)
Feb 14, 2020
This proven strategy can give big returns in quick time.
The Top 8 Trading Mistakes You Should Avoid (Fast Profits Daily)
Feb 18, 2020Avoid these mistakes and your trading will turn much more profitable.
These Rebirth of India Stocks Are Raring to Compete with Tesla (The 5 Minute Wrapup)
Feb 17, 2020There are Indian stocks which can soar like Tesla in the long-run.
More